Wednesday, May 20, 2020 7:13:51 AM
georgie18 Saturday, 05/02/20 10:45:12 AM
Re: LINK Oracle post# 1419 0
Post #
1421
of 1449
OCGN...336...Bullish Meeting Line Reversal Pattern formed here followed by a 25 Million Green Volume Spike...A/D Line ...Money Flow just spotting the Reversal... Aroon confirms the Trend Reversal to the Upside ...longer term "W" Pattern setting up here...Break/Hold 85 range is the confirmation...Resistance Neckline at $12 range...Next target if the Break/Hold of .85 is confirmed is the 200ma...followed by the Resistance Neckline...imo...we shall see...
Take Profits Relentlessly...Candlesticks the art of learning how to buy Bearish before it turns to Bullish and how to sell the Bullish before it turns Bearish...
Recent OCGN News
- Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy • GlobeNewswire Inc. • 04/19/2024 11:13:05 AM
- Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets • GlobeNewswire Inc. • 04/12/2024 11:30:34 AM
- Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 04/10/2024 11:02:26 AM
- Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 04/08/2024 10:30:43 AM
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy • GlobeNewswire Inc. • 04/05/2024 11:02:21 AM
- Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 • GlobeNewswire Inc. • 04/02/2024 12:00:39 PM
- Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 04/01/2024 10:08:46 PM
- Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 • GlobeNewswire Inc. • 04/01/2024 09:43:45 PM
- Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 10:30:50 AM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 • GlobeNewswire Inc. • 03/13/2024 12:00:54 PM
- Ocugen to Present at Investing in Cures Summit • GlobeNewswire Inc. • 03/06/2024 12:30:09 PM
- Ocugen Clinical Showcase Webcast Now Available • GlobeNewswire Inc. • 02/28/2024 01:00:26 PM
- Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit • GlobeNewswire Inc. • 02/26/2024 01:30:13 PM
- Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Ocugen to Present at 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/21/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 04:22:29 PM
- Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 • GlobeNewswire Inc. • 02/14/2024 12:30:49 PM
- Ocugen to Present at Pharma Market Research Conference • GlobeNewswire Inc. • 01/31/2024 01:00:12 PM
- Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board • GlobeNewswire Inc. • 01/16/2024 12:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:05:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:47:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:47:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:04:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 08:09:27 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM